Sara Onali
Cagliari, 09124, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Patients with Crohn's Disease Achieving Ustekinumab-Induced Remission Are Characterized by Increased Baseline IL-23 Receptor Expression on Lamina Propria Th1 Cells.
Journal: Journal of clinical medicine
Published: May 17, 2026
The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease-related spondyloarthritis: insights from a cross-sectional study.
Journal: Frontiers in medicine
Published: March 06, 2026
Optimizing Malnutrition Risk Detection in Inflammatory Bowel Disease: A Longitudinal Analysis of Serial Nutritional Screening Tools.
Journal: Nutrients
Published: December 30, 2025
Pathogenesis of Eosinophilic Esophagitis: A PRISMA-based systematic review of Genetic, Immunological and Molecular Drivers.
Journal: Clinical and translational gastroenterology
Published: December 11, 2025
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
Journal: Journal of Crohn's & colitis
Published: November 03, 2025
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
Journal: Journal of Crohn's & colitis
Published: November 03, 2025
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.
Journal: The American journal of gastroenterology
Published: October 27, 2025
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: October 07, 2025
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: October 07, 2025
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: October 07, 2025
Interplay Between Depression and Inflammatory Bowel Disease: Shared Pathogenetic Mechanisms and Reciprocal Therapeutic Impacts-A Comprehensive Review.
Journal: Journal of clinical medicine
Published: July 01, 2025
Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: May 13, 2025
Last Updated: 09/26/2026